Deleting B7-H3 in tumour cells and using anti-PD-L1 treatment restored NK cell function and enhanced cytotoxicity against NPC cells in xenograft models, suggesting the potential when combined with NK cell-based immunotherapy and immune checkpoint blockade against EBV-associated NPC (79). The gene discussed is CD276; the disease is nasopharyngeal carcinoma.